The primary endpoint was ORR in all treated patients and PD-L1+ patients (defined as PD-L1 ≥5%, and after an amendment, ≥1%; PD-L1 expression was assessed on tumor cells through the Dako system); secondary endpoints were PFS and OS. This evidence concerns the gene CD274 and neoplasm.